



Crystal structure of (Z)-3-hydroxy-3-(4-methoxyphenyl)-1-(pyridin-2-yl)prop-2-en-1-one, C₁₅H₁₃NO₃

Smaail Radi, Said Tighadouini, Driss Eddike, Yahia N. Mabkhot, Monique Tillard

► To cite this version:

Smaail Radi, Said Tighadouini, Driss Eddike, Yahia N. Mabkhot, Monique Tillard. Crystal structure of (Z)-3-hydroxy-3-(4-methoxyphenyl)-1-(pyridin-2-yl)prop-2-en-1-one, C₁₅H₁₃NO₃. Zeitschrift für Kristallographie - New Crystal Structures, 2017, 232 (2), pp.235-236. 10.1515/nocrs-2016-0219 . hal-01491964

HAL Id: hal-01491964

<https://hal.science/hal-01491964>

Submitted on 6 Jul 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.


L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Smaail Radi*, Said Tighadouini, Driss Eddike, Yahia N. Mabkhot* and Monique Tillard*

Crystal structure of (Z)-3-hydroxy-3-(4-methoxyphenyl)-1-(pyridin-2-yl)prop-2-en-1-one, C₁₅H₁₃NO₃



DOI 10.1515/ncls-2016-0219

Received July 27, 2016; accepted January 3, 2017; available online January 18, 2017

Abstract

C₁₅H₁₃NO₃, monoclinic, Cc (No. 9), $a = 3.9230(3)$ Å, $b = 26.578(2)$ Å, $c = 11.7147(12)$ Å, $\beta = 94.028(8)^\circ$, $V = 1218.4(2)$ Å³, $Z = 4$, $R_{\text{gt}}(F) = 0.0387$, $wR_{\text{ref}}(F^2) = 0.0877$, $T = 173$ K.

CCDC no.: 1525410

The asymmetric unit of the title crystal structure is shown in the figure. Tables 1 and 2 contain details of the measurement method and a list of the atoms including atomic coordinates and displacement parameters.

Source of material

To a suspension of sodium (0.4 g; 17.40 mmol) in anhydrous toluene, was added ethyl 2-picoline (2 g; 13.28 mmol) in toluene. Then 1-(4-methoxphenyl) ethanone (1.99 g;

*Corresponding authors: Smaail Radi, LCAE, Department of Chemistry, Faculty of Sciences, Mohamed Premier University, Oujda 60000, Morocco; and Yahia N. Mabkhot, Department of Chemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh 1451, Saudi Arabia; and Monique Tillard, Institut Charles Gerhardt, AIME, UMR CNRS 5253 CC1502, Université de Montpellier, 2 Place Eugène Bataillon, 34095 Montpellier Cedex 5, France, e-mail: mtillard@univ-montp2.fr

Said Tighadouini: LCAE, Department of Chemistry, Faculty of Sciences, Mohamed Premier University, Oujda 60000, Morocco

Driss Eddike: LCSMA, Faculté des Sciences, Université Mohamed I, 60000 Oujda, Morocco

Table 1: Data collection and handling.

Crystal:	Colourless platelet
Size:	0.50 × 0.15 × 0.06 mm
Wavelength:	Mo K α radiation (0.71073 Å)
μ :	1.0 cm ⁻¹
Diffractometer, scan mode:	Xcalibur Sapphire3, ω -scans
2 θ _{max} , completeness:	58.6°, >87%
$N(hkl)$ _{measured} , $N(hkl)$ _{unique} , R_{int} :	6523, 2714, 0.024
Criterion for I_{obs} , $N(hkl)$ _{gt} :	$I_{\text{obs}} > 2 \sigma(I_{\text{obs}})$, 2410
$N(\text{param})$ _{refined} :	181
Programs:	CrysAlis ^{PRO} [8], SHELX [9], ORTEP [10]

13.28 mmol) was added at 0 °C. The resulting mixture was stirred at room temperature for 7 days. The precipitate formed was filtered, washed and dissolved in water. The neutralized solution was extracted with CH₂Cl₂, and the organic layer was dried and concentrated *in vacuo*. The obtained residue was chromatographed on silica using CH₂Cl₂/MeOH as eluant to give the desired product. Crystals of the title compound were obtained from hot ethanol by slow evaporation. Yield: 33%, M.p. 112–114 °C.

Experimental details

The structure has been first solved in a triclinic unit cell of parameters $a = 7.85$, $b = 11.72$, $c = 13.43$ Å, $\alpha = 89.4$, $\beta = 81.6$, $\gamma = 86.0^\circ$. The unit cell contains four independant molecules. Final refinement in these conditions with anisotropic displacement parameters led to an agreement factor R1 = 4.59%. Except the freely refined H atoms that display rather high standard deviations for which positions are not precisely determined, the four molecules are symmetry-related and it became obvious that the cell must be transformed to the monoclinic cell described here (−.5 0 0 −.5 0 2 0 1 0). Final refinement in the monoclinic space group improves the agreement factor to 3.87%. The acidic hydrogen atom is placed between O1 and O2 atoms. This would indicate that this H atom is easily exchangeable between the two oxygen atoms.

Table 2: Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å²).

Atom	x	y	z	<i>U</i> _{iso} */* <i>U</i> _{eq}
C1	-0.1882(5)	-0.36669(8)	-0.2671(2)	0.0259(5)
C2	-0.2952(6)	-0.36593(9)	-0.3825(2)	0.0267(6)
C3	-0.2108(5)	-0.40601(8)	-0.4539(2)	0.0249(5)
C4	-0.3192(6)	-0.40770(8)	-0.5771(2)	0.0241(5)
C5	-0.2310(6)	-0.44855(8)	-0.6429(2)	0.0266(5)
H5	-0.1015	-0.4752	-0.6074	0.032*
C6	-0.3270(5)	-0.45148(9)	-0.7591(2)	0.0269(6)
H6	-0.2665	-0.4799	-0.8024	0.032*
C7	-0.5126(5)	-0.41221(9)	-0.8110(2)	0.0246(5)
C8	-0.6015(6)	-0.37083(9)	-0.7473(2)	0.0282(6)
H8	-0.7275	-0.3440	-0.7834	0.034*
C9	-0.5073(5)	-0.36858(9)	-0.6318(2)	0.0268(5)
H9	-0.5705	-0.3402	-0.5888	0.032*
C10	-0.5131(6)	-0.45106(9)	-0.9946(2)	0.0320(6)
H10A	-0.6025	-0.4831	-0.9682	0.048*
H10B	-0.2629	-0.4523	-0.9901	0.048*
H10C	-0.5990	-0.4451	-1.0741	0.048*
C11	-0.2740(6)	-0.32595(8)	-0.1876(2)	0.0267(5)
C12	-0.1731(6)	-0.32924(9)	-0.0722(2)	0.0316(6)
H12	-0.0481	-0.3576	-0.0427	0.038*
C13	-0.2582(7)	-0.29035(10)	-0.0005(2)	0.0368(6)
H13	-0.1917	-0.2915	0.0790	0.044*
C14	-0.4396(6)	-0.25025(10)	-0.0461(2)	0.0357(6)
H14	-0.5014	-0.2231	0.0010	0.043*
C15	-0.5309(7)	-0.25009(10)	-0.1626(3)	0.0360(6)
H15	-0.6576	-0.2222	-0.1934	0.043*
H1	-0.435(7)	-0.3384(10)	-0.409(2)	0.032(7)*
H2	0.019(11)	-0.4269(17)	-0.312(4)	0.099(14)*
N	-0.4521(5)	-0.28662(7)	-0.23402(19)	0.0314(5)
O1	-0.0315(4)	-0.44320(6)	-0.41288(16)	0.0320(4)
O2	-0.0054(5)	-0.40355(6)	-0.22220(17)	0.0348(4)
O3	-0.6225(4)	-0.41111(6)	-0.92382(15)	0.0310(4)

Discussion

Compounds incorporating a β-ketoenol moiety have yielded clinical integrase inhibitor drug candidates [1]. Tomassini et al. reported a series of β-ketoenol derivatives as effective inhibitors drug of influenza viral replication in both *in vitro* cell culture replication assays and *in vivo* mouse challenge model, without exhibiting any cytotoxicity [2–4]. Furthermore, complexes with β-ketoenols have received more attention in the area of medicinal chemistry [5], exhibiting anticancer activity against several tumoral cells strains [6], and cytotoxic activity in a chronic myelogenous leukemia cell line [7]. Herein, we report the preparation of a new pyridine incorporating a β-ketoenol moiety: (Z)-3-hydroxy-3-(4-methoxyphenyl)-1-(pyridin-2-yl) prop-2-en-1-one in moderate yield.

The crystal structure shows that the oxygen atoms share the same hydrogen atom placed just in between O1 and O2. This is due to the fact that each of the two atoms O1 and O2 alternately ensure the enole and ketone functions, and

are involved in a tautomer effect as reflected by the close distances C3–O1 1.287(3) and C1–O2 1.303(3) Å. The C4, C5, C6, C7, C8 and C9 atoms are in the same plane. The torsion angle O1 C3 C4 C9 of 178.2(2)° indicates that the benzene ring undergoes slight inclination with respect to the C3–C4 bond. Also the 2-pyridinyl moiety are in the same plane, while the torsion angle O2–C1–C11–N of -177.5(2)° indicate that the plane of pyridine ring undergoes also a slight inclination relative to plane of the rest of the molecule.

Acknowledgements: The authors extend their appreciation to the PPR2-MESRSFC-CNRST-P10 project (Morocco). Sincere appreciation was also extended to the Deanship of Scientific Research at King Saud University for its supporting this Prolific Research group (PRG-1437-29).

References

- Dayam, R.; Deng, J.; Neamati, N.: HIV-1 integrase inhibitors: 2003-2004 update. *Med. Res. Rev.* **26** (2006) 271–309.
- Tomassini, J. E.; Selnick, H.; Davies, M. E.; Armstrong, M. E.; Baldwin, J.; Bourgeois, M.; Hastings, J.; Hazuda, D.; Lewis, J.; McClements, W.: Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. *Antimicrob. Agents Chemother.* **38** (1994) 2827–2837.
- Tomassini, J. E.; Davies, M. E.; Hastings, J. C.; Lingham, R.; Mojena, M.; Raghoobar, S. L.; Singh, S. B.; Tkacz, J. S.; Goetz, M. A.: A novel antiviral agent which inhibits the endonuclease of influenza viruses. *Antimicrob. Agents Chemother.* **40** (1996) 1189–1193.
- Hastings, J. C.; Selnick, H.; Wolanski, B.; Tomassini, J. E.: Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors. *Antimicrob. Agents Chemother.* **40** (1996) 1304–1307.
- Almeida, J. C.; Marzano, I. M.; Silva de Paula, F. C.; Pivatto, M.; Lopes, N. P.; deSouza, P. C.; Pavan, F. R.; Formiga, A. L. B.; Pereira-Maia, E. C.; Guerra, W.: Complexes of platinum and palladium with β-diketones and DMSO: Synthesis, characterization, molecular modeling, and biological studies. *J. Mol. Struct.* **1075** (2014) 370–376.
- Wilson, J. J.; Lippard, S. J.: In vitro anticancer activity of cis-diammineplatinum(II) complexes with β-diketonate leaving group ligands. *J. Med. Chem.* **55** (2012) 5326–5336.
- Almeida, J. D. C.; Paixao, D. A.; Marzano, I. M.; Ellena, J.; Pivatto, M.; Lopes, N. P.; Ferreira, A. M. D. C.; Pereira-Maia, E. C.; Guilardi, S.; Guerra, W.: Copper(II) complexes with β-diketones and N-donor heterocyclic ligands: Crystal structure, spectral properties, and cytotoxic activity. *Polyhedron* **89** (2015) 1–8.
- Rigaku Oxford Diffraction. CrysAlis PRO Software system, version 1.171.38.41, Rigaku Corporation, Oxford, UK, 2016.
- Sheldrick, G. M.: A short history of SHELX. *Acta Crystallogr. A* **64** (2008) 112–122.
- Farrugia, L. J.: WinGX, ORTEP for Windows, an update. *J. Appl. Crystallogr.* **45** (2012) 849–854.